Stock listing
OTC:SBMJF Dimerix Limited Stock
US listing (OTC) of Dimerix Limited · home listing ASX:DXB
Follow Dimerix Limited into a list and get an email when it puts out news.
Home listing price · ASX:DXB
$0.185 AUD 0.000 (0.0%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, ASX:DXB
- Day range
- $0.180 – $0.190 AUDNov 20, 2026
- Volume
- 559,775 sharesNov 20, 2026
- Market cap
- $111.1M AUDAt the close on Nov 20, 2026 · price × 600.4M shares outstanding
- 52-week range
- $0.158 – $0.665 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $177,022 AUDMedian day 621,128 shares · 2 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| ASX:DXB · Home | $0.185 AUD | 0.000 (0.0%) | 559,775 | $0.190 | $0.190 | $0.180 | $0.185 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:DXB · AUD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.185 | 0.000 | 0.0% | $0.190 | $0.190 | $0.180 | 559,775 | |
| $0.185 | -0.010 | -5.1% | $0.195 | $0.195 | $0.185 | 413,982 | |
| $0.195 | 0.000 | 0.0% | $0.195 | $0.200 | $0.190 | 855,490 | |
| $0.195 | -0.005 | -2.5% | $0.210 | $0.210 | $0.195 | 600,338 | |
| $0.200 | 0.000 | 0.0% | $0.200 | $0.210 | $0.200 | 739,754 | |
| $0.200 | -0.015 | -7.0% | $0.215 | $0.215 | $0.200 | 1,265,783 | |
| $0.215 | -0.005 | -2.3% | $0.210 | $0.225 | $0.210 | 1,108,379 | |
| $0.220 | 0.000 | 0.0% | $0.210 | $0.220 | $0.210 | 487,944 | |
| $0.220 | +0.015 | +7.3% | $0.210 | $0.220 | $0.205 | 593,069 | |
| $0.205 | -0.005 | -2.4% | $0.205 | $0.210 | $0.205 | 413,216 | |
| $0.210 | +0.010 | +5.0% | $0.200 | $0.222 | $0.200 | 1,032,400 | |
| $0.200 | -0.010 | -4.8% | $0.210 | $0.210 | $0.200 | 411,563 | |
| $0.210 | 0.000 | 0.0% | $0.210 | $0.210 | $0.205 | 165,895 | |
| $0.210 | 0.000 | 0.0% | $0.210 | $0.215 | $0.205 | 636,778 | |
| $0.210 | -0.005 | -2.3% | $0.215 | $0.220 | $0.210 | 333,872 | |
| $0.215 | +0.010 | +4.9% | $0.210 | $0.225 | $0.210 | 462,081 | |
| $0.205 | +0.005 | +2.5% | $0.210 | $0.215 | $0.200 | 736,782 | |
| $0.200 | 0.000 | 0.0% | $0.205 | $0.205 | $0.195 | 178,868 | |
| $0.200 | +0.005 | +2.6% | $0.200 | $0.200 | $0.195 | 33,422 | |
| $0.195 | -0.010 | -4.9% | $0.215 | $0.215 | $0.195 | 1,061,694 | |
| $0.205 | -0.005 | -2.4% | $0.200 | $0.210 | $0.200 | 300,416 | |
| $0.210 | +0.005 | +2.4% | $0.210 | $0.215 | $0.200 | 260,743 | |
| $0.205 | -0.005 | -2.4% | $0.205 | $0.215 | $0.205 | 194,898 | |
| $0.210 | -0.010 | -4.5% | $0.230 | $0.230 | $0.208 | 692,566 | |
| $0.220 | +0.010 | +4.8% | $0.210 | $0.225 | $0.210 | 552,845 | |
| $0.210 | 0.000 | 0.0% | $0.215 | $0.215 | $0.195 | 1,137,925 | |
| $0.210 | -0.010 | -4.5% | $0.215 | $0.220 | $0.210 | 238,108 | |
| $0.220 | 0.000 | 0.0% | $0.215 | $0.220 | $0.215 | 272,987 | |
| $0.220 | 0.000 | 0.0% | $0.240 | $0.240 | $0.218 | 438,080 | |
| $0.220 | 0.000 | 0.0% | $0.225 | $0.228 | $0.215 | 325,000 | |
| $0.220 | -0.005 | -2.2% | $0.225 | $0.230 | $0.220 | 438,756 | |
| $0.225 | -0.005 | -2.2% | $0.225 | $0.230 | $0.220 | 638,201 | |
| $0.230 | -0.005 | -2.1% | $0.240 | $0.240 | $0.225 | 975,412 | |
| $0.235 | +0.010 | +4.4% | $0.225 | $0.245 | $0.225 | 830,659 | |
| $0.225 | -0.010 | -4.3% | $0.230 | $0.230 | $0.225 | 402,282 | |
| $0.235 | +0.005 | +2.2% | $0.235 | $0.235 | $0.225 | 525,796 | |
| $0.230 | 0.000 | 0.0% | $0.235 | $0.235 | $0.225 | 271,613 | |
| $0.230 | -0.005 | -2.1% | $0.235 | $0.240 | $0.225 | 387,718 | |
| $0.235 | +0.010 | +4.4% | $0.235 | $0.235 | $0.225 | 686,422 | |
| $0.225 | -0.010 | -4.3% | $0.235 | $0.235 | $0.225 | 605,478 | |
| $0.235 | 0.000 | 0.0% | $0.240 | $0.240 | $0.230 | 1,094,284 | |
| $0.235 | -0.005 | -2.1% | $0.240 | $0.240 | $0.230 | 1,414,555 | |
| $0.240 | +0.005 | +2.1% | $0.240 | $0.240 | $0.235 | 305,261 | |
| $0.235 | -0.010 | -4.1% | $0.255 | $0.255 | $0.235 | 927,640 | |
| $0.245 | 0.000 | 0.0% | $0.245 | $0.255 | $0.240 | 1,558,801 | |
| $0.245 | +0.005 | +2.1% | $0.240 | $0.245 | $0.235 | 286,203 | |
| $0.240 | +0.005 | +2.1% | $0.245 | $0.245 | $0.230 | 849,293 | |
| $0.235 | -0.005 | -2.1% | $0.240 | $0.245 | $0.235 | 817,578 | |
| $0.240 | -0.010 | -4.0% | $0.250 | $0.275 | $0.240 | 765,446 | |
| $0.250 | 0.000 | 0.0% | $0.250 | $0.255 | $0.245 | 810,805 | |
| $0.250 | -0.010 | -3.8% | $0.270 | $0.270 | $0.250 | 1,392,741 | |
| $0.260 | -0.010 | -3.7% | $0.270 | $0.270 | $0.260 | 1,125,101 | |
| $0.270 | -0.010 | -3.6% | $0.275 | $0.280 | $0.270 | 815,693 | |
| $0.280 | -0.005 | -1.8% | $0.290 | $0.290 | $0.275 | 899,948 | |
| $0.285 | -0.005 | -1.7% | $0.305 | $0.310 | $0.280 | 2,999,082 | |
| $0.290 | 0.000 | 0.0% | $0.290 | $0.290 | $0.290 | 0 | |
| $0.290 | 0.000 | 0.0% | $0.290 | $0.290 | $0.290 | 0 | |
| $0.290 | +0.010 | +3.6% | $0.275 | $0.290 | $0.275 | 408,682 | |
| $0.280 | +0.005 | +1.8% | $0.280 | $0.280 | $0.260 | 1,368,829 | |
| $0.275 | -0.015 | -5.2% | $0.285 | $0.295 | $0.275 | 572,986 | |
| $0.290 | 0.000 | 0.0% | $0.295 | $0.295 | $0.285 | 710,477 | |
| $0.290 | -0.025 | -7.9% | $0.310 | $0.310 | $0.290 | 1,791,495 | |
| $0.315 | +0.005 | +1.6% | $0.305 | $0.315 | $0.305 | 587,104 | |
| $0.310 | 0.000 | 0.0% | $0.315 | $0.315 | $0.305 | 696,317 | |
| $0.310 | -0.015 | -4.6% | $0.325 | $0.330 | $0.308 | 1,167,459 | |
| $0.325 | +0.030 | +10.2% | $0.305 | $0.325 | $0.300 | 2,234,026 |
Splits
6 splits since 1995 · ASX:DXB · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation | |
| 1-for-14 | Consolidation | |
| 5-for-3 | Split | |
| 2-for-5 | Consolidation | |
| 14-for-11 | Split | |
| 26-for-25 | Split |
- Ticker
- OTC:SBMJF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Oct 28, 2026
Dimerix Quarterly Activities Report and Appendix 4C
Latest deck · Oct 23, 2026
Technical Presentation (October 2026)
Technical · 17 slides
Latest news
Final Director's Interest Notice - MD
Nov 5, 2026
Closed $0.205 (-2.4%) on Nov 6, 2026
Dimerix Quarterly Activities Report and Appendix 4C
Oct 28, 2026
Closed $0.215 (+4.9%) on Oct 29, 2026
New Data Supports Biological Rationale for DMX-200 in FSGS
Oct 22, 2026
Closed $0.195 (-4.9%) on Oct 23, 2026
2026 AGM Notice of Meeting, Letter of Access and Proxy Form
Oct 21, 2026
Closed $0.205 (-2.4%) on Oct 22, 2026
Dimerix Announces Board Chair Transition
Oct 18, 2026
Closed $0.21 (-4.5%) on Oct 19, 2026
DMX-200 First 100 Patients Complete Phase 3 Trial Treatment
Oct 15, 2026
Closed $0.22 (+4.8%) on Oct 16, 2026
Dimerix at Canaccord Drug & Device and Ignite Conferences
Oct 11, 2026
Closed $0.22 (0.0%) on Oct 12, 2026
First Patient Reaches Four Years in DMX-200 Clinical Program
Oct 4, 2026
Closed $0.235 (+4.4%) on Oct 5, 2026
Notification regarding unquoted securities - DXB
Sep 28, 2026
Closed $0.235 (+4.4%) on Sep 28, 2026
Notification of 2026 Annual General Meeting Date
Sep 25, 2026
Closed $0.225 (-4.3%) on Sep 25, 2026
Dimerix Limited on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 44 in the last 12 months · 248 in all · newest Nov 5, 2026 · oldest 2016
- Decks
- 86 decks · latest Oct 23, 2026
Where Dimerix Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| ASX:DXB · Home listing | ASX | Australia | AUD |
| OTC:SBMJF · This page | OTC | United States | USD |
Cash and shares
Sep 15, 2026 · Dimerix — ASX SMIDcaps Conference 2026
- Shares outstanding
- 600,396,776
Valuation
EV/sales 21.9× against a median of 68.3×: 4th lowest of 7 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $95.15M AUD
- P/E
- Loss
- EV/sales
- 21.9×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 96.8%
- Operating margin
- −854.6%
- Net margin
- −685.3%
- Debt to equity
- Negative equity
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Dimerix Limited · ASX:DXB | US$73.52M | US$62.98M | n/a | 21.9× | n/a | n/a | −685.3% | n/a | n/a |
| HLB Therapeutics Co., Ltd. · KRX:115450 | US$76.35M | US$66.52M | n/a | 1.4× | n/a | 0.7× | −28.0% | 0.0× | n/a |
| Recce Pharmaceuticals Ltd. · ASX:RCE | US$75.90M | US$81.02M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Black Diamond Therapeutics, Inc. · NASDAQ:BDTX | US$75.28M | −US$10.71M | n/a | n/a | n/a | 0.8× | n/a | 0.2× | 1.76 |
| Great Novel Therapeutics Biotech & Medicals Corp. · TPEX:7427 | US$73.92M | US$52.72M | n/a | 1,442× | n/a | 3.2× | n/a | 0.0× | n/a |
| Pentixapharm Holding AG · XETR:PTP | US$73.87M | US$69.92M | n/a | 1,158× | n/a | 2.4× | n/a | 0.0× | n/a |
| Faron Pharmaceuticals Oy · LSE:FARN | US$72.99M | US$57.36M | n/a | n/a | n/a | 5.7× | n/a | 1.5× | n/a |
| Cellectis S.A. · EURONEXT:ALCLS | US$72.64M | −US$9.64M | n/a | −0.2× | n/a | 1.8× | −115.4% | 2.1× | n/a |
| Kanaph Therapeutics Inc. · KRX:0082N0 | US$72.37M | US$38.83M | n/a | 9.3× | n/a | 2.1× | −729.8% | 0.0× | n/a |
| Eastwood Bio-Medical Canada Inc · TSXV:EBM | US$72.05M | US$72.05M | n/a | 127× | n/a | n/a | −28.5% | n/a | 0.56 |
| SynAct Pharma AB · OMXSTO:SYNACT | US$71.29M | US$71.60M | n/a | n/a | n/a | 5.1× | n/a | 0.3× | n/a |
| Median of the others | US$73.43M | US$61.94M | 68.3× | 2.2× | −71.9% | 0.1× | 1.16 |
Team and board
Officers
| Officer | Role |
|---|---|
| Nina Webster | Chief Executive Officer / Managing Director |
| Mike Tonroe | Chief Financial Officer & Company Secretary |
| Robert Shepherd | Chief Operating Officer |
| David Fuller | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Mark Diamond | Non-Executive Chairman |
| Clinton Snow | Non-Executive Director |
| Hugh Alsop | Non-Executive Director |
| Sonia Poli | Non-Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Aug 27, 2025 | −5.3% |
| Q2 2025 | Feb 24, 2025 | +1.0% |
| Q2 2023 | Feb 26, 2023 · After close | −4.2% |
| Q4 2022 | Aug 28, 2022 · After close | −12.5% |
| Q2 2022 | Feb 23, 2022 · After close | −2.1% |
| Q4 2021 | Aug 15, 2021 | +42.5% |
| Q2 2021 | Feb 22, 2021 | −5.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (October 2026) | Technical | 17 slides | Oct 23, 2026 |
| Canaccord Genuity Drug and Device Conference 2026 | Conference | 35 slides | Oct 12, 2026 |
| ASX SMIDcaps Conference 2026 | Conference | 16 slides | Sep 23, 2026 |
| E&P Healthcare Conference 2026 | Conference | 22 slides | Sep 16, 2026 |
| Investor Presentation (September 2026) | Investor deck | 35 slides | Sep 7, 2026 |
| TechKnow Invest Roadshow (July 2026) | Conference | 16 slides | July 2026 |
| Investor Presentation (April 2026) | Investor deck | 26 slides | Apr 28, 2026 |
| Euroz Hartleys Institutional Conference 2026 | Conference | 26 slides | Mar 19, 2026 |
| Investor Presentation (March 2026) | Investor deck | 26 slides | March 2026 |
| Oppenheimer 36th Annual Healthcare Life Sciences Conference (February 2026) | Conference | 24 slides | Feb 26, 2026 |
Show 50 decks
This page holds 50 of 86 decks. Open Decks
Financials
Annual, in AUD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.35M | 1.25M | 583.5K | 36.8K | 6.46M | 4.44M | 2.34M | 1.45M | 845.3K | 554.6K |
| Cost of revenue | 138.2K | 56.0K | 50.5K | 44.6K | 13.5K | 4.68K | 6.42K | 1.52K | ||
| Gross profit | 4.21M | 1.25M | 583.5K | 36.8K | 6.41M | 4.39M | 2.33M | 1.44M | 838.9K | 553.1K |
| Research and development | 36.0M | 27.3M | 21.1M | 20.5M | 14.4M | 9.33M | 5.54M | 2.84M | 2.05M | 878.1K |
| Selling, general and administrative | 5.04M | 4.89M | 3.12M | 2.28M | 2.44M | 1.56M | 1.30M | 1.21M | 1.40M | 1.38M |
| Operating income | -37.2M | -36.3M | -25.2M | -22.8M | -10.5M | -10.9M | -6.92M | -4.33M | -4.17M | -2.31M |
| Depreciation and amortization | 138.2K | 123.6K | 48.7K | 56.0K | 50.5K | 44.6K | 13.5K | 4.68K | 6.42K | 1.52K |
| EBITDA | -37.0M | -36.2M | -25.2M | -22.8M | -10.4M | -10.9M | -6.90M | -4.33M | -4.16M | -2.31M |
| Interest expense | 1.16K | 0 | 0 | 0 | 0 | 0 | ||||
| Income before tax | -36.6M | -31.7M | -17.1M | -13.8M | -10.5M | -10.1M | -6.83M | -4.32M | -4.14M | -2.29M |
| Income tax | -6.74M | -18.4M | -7.93M | -8.94M | -6.03M | -3.70M | -2.34M | -1.43M | -825.0K | -536.0K |
| Net income | -29.8M | -13.3M | -17.1M | -13.8M | -10.5M | -6.37M | -4.49M | -2.89M | -3.32M | -1.76M |
| Earnings per share, basic | -0.05 | -0.02 | -0.04 | -0.04 | -0.04 | -0.03 | -0.03 | -0.02 | -0.03 | -0.02 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 16.2M | 68.3M | 22.1M | 7.99M | 9.63M | 5.25M | 7.79M | 3.56M | 6.28M | 2.24M |
| Receivables | 18.6M | 3.64M | 9.52M | 9.55M | 6.39M | 4.01M | 2.46M | 1.27M | 903.5K | 577.2K |
| Inventory | 184.3K | 400.6K | 118.5K | 107.6K | -1.27M | -903.5K | -577.2K | |||
| Current assets | 35.1M | 72.2M | 31.9M | 17.8M | 16.5M | 9.42M | 10.4M | 4.94M | 7.26M | 2.87M |
| Property, plant and equipment | 117.6K | 162.4K | 6.41K | 8.61K | 1.42K | 1.23K | 2.62K | 391 | 3.27K | |
| Total assets | 58.6M | 91.2M | 32.1M | 17.8M | 16.5M | 9.42M | 10.4M | 4.94M | 7.26M | 2.87M |
| Accounts payable | 2.28M | 14.1M | 305.2K | 5.14M | 1.11M | 2.52M | 1.15M | 416.8K | 269.3K | 83.4K |
| Current liabilities | 9.18M | 22.2M | 3.36M | 11.8M | 2.02M | 7.95M | 2.63M | 737.8K | 406.7K | 242.1K |
| Total debt | 232.1K | 97.5K | 149.7K | 5.96M | 73.1K | 5.09M | 1.06M | 1.09M | ||
| Total liabilities | 73.3M | 77.8M | 13.9M | 11.8M | 2.07M | 7.95M | 2.63M | 737.8K | 406.7K | 242.1K |
| Shareholders' equity | -14.8M | 13.4M | 18.2M | 5.96M | 14.4M | 1.47M | 7.76M | 4.20M | 6.86M | 2.63M |
| Shares outstanding | 600.3M | 560.4M | 452.9M | 325.5M | 299.5M | 201.4M | 174.6M | 161.4M | 117.5M | 86.8M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -51.8M | 39.1M | -7.00M | -12.7M | -13.4M | -6.46M | -4.72M | -2.75M | -3.23M | -1.86M |
| Capital spending | -4.98K | -21.0K | -15.8K | -2.30K | -10.6K | -9.57K | -9.57K | -6.91K | -3.54K | -2.58K |
| Free cash flow | -51.8M | 39.0M | -7.02M | -12.7M | -13.4M | -6.47M | -4.72M | -2.76M | -3.23M | -1.87M |
| Cash from investing | -4.98K | -21.0K | -15.8K | -2.30K | -10.6K | 4.38K | 4.38K | -6.91K | -3.54K | -2.58K |
| Cash from financing | 118.5K | 7.42M | 21.2M | 11.1M | 17.7M | 3.83M | 8.91M | 8.91M | 7.25M | 2.09M |
| Dividends paid | -10.7M | -1.40K | -1.24M | -8.48M | ||||||
| Share buybacks | 7.55M | -1.40M | -444.6K | -1.24M | -1.24M | -441.4K | -441.4K | -371.5K | -128.1K | |
| Change in cash | -52.1M | 46.1M | 14.1M | -1.64M | 4.38M | -2.54M | 4.22M | -2.72M | 4.04M | 225.8K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Final Director's Interest Notice - MD | Nov 5, 2026 | Ownership change notice | ASX |
| Dimerix Quarterly Activities Report and Appendix 4C | Oct 28, 2026 | Quarterly report | ASX |
| Dimerix Quarterly Activities Report and Appendix 4C | Oct 28, 2026 | Quarterly report | ASX |
| New Data Supports Biological Rationale for DMX-200 in FSGS | Oct 22, 2026 | Other filings | ASX |
| 2026 AGM Notice of Meeting, Letter of Access and Proxy Form | Oct 21, 2026 | Meeting notice | ASX |
| Dimerix Announces Board Chair Transition | Oct 18, 2026 | Management or board change | ASX |
| DMX-200 First 100 Patients Complete Phase 3 Trial Treatment | Oct 15, 2026 | Operations update | ASX |
| Dimerix at Canaccord Drug & Device and Ignite Conferences | Oct 11, 2026 | Operations update | ASX |
| First Patient Reaches Four Years in DMX-200 Clinical Program | Oct 4, 2026 | Other filings | ASX |
| Notification regarding unquoted securities - DXB | Sep 28, 2026 | Other filings | ASX |
Show 200 filings
This page holds 200 of 242 filings. Open Filings
Cap table
Built by 6ix from Dimerix Limited’s releases
- Common shares
- 600,396,776
- Fully diluted
- 600,396,776
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 600,396,776 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 600,396,776 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Clinton Snow | Non-Executive Director · Since at least Nov 5, 2026 |
| David Fuller | Chief Medical Officer · Since at least Apr 28, 2026 |
| Hugh Alsop | Non-Executive Director · Since at least Nov 5, 2026 |
| Mark Diamond | Non-Executive Chairman · Since at least Nov 5, 2026 |
| Mike Tonroe | Chief Financial Officer & Company Secretary · Since at least Nov 4, 2026 |
| Nina Webster | Chief Executive Officer / Managing Director · Since at least Sep 22, 2026 |
| Robert Shepherd | Chief Operating Officer · Since at least Nov 5, 2026 |
| Sonia Poli | Non-Executive Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Dimerix Limited.